TY - JOUR
T1 - Prognostic value of disease distribution in secondary central nervous system diffuse large B cell lymphoma treated with radiation therapy
AU - Al Feghali, Karine A.
AU - Fang, Penny
AU - Gule-Monroe, Maria
AU - Milgrom, Sarah
AU - Khoury, Joseph D.
AU - Gunther, Jillian R.
AU - Sheu, Tommy
AU - Nair, Ranjit
AU - Ahmed, Sairah
AU - Steiner, Raphael
AU - Strati, Paolo
AU - Shpall, Elizabeth J.
AU - Nieto, Yago L.
AU - Hosing, Chitra
AU - Nastoupil, Loretta J.
AU - Westin, Jason R.
AU - Neelapu, Sattva S.
AU - Fowler, Nathan
AU - Flowers, Christopher
AU - Pinnix, Chelsea C.
AU - Dabaja, Bouthaina S.
N1 - Funding Information:
This work was supported by Cancer Center Support Grant [CA016672].
Funding Information:
CCP has received research funding from Merck. LJN has received honorarium from Bayer, Celgene, Gamida Cell, Genentech, GILEAD/KITE, Janssen, Novartis, TG Therapeutics. LJN has received research funding from Celgene, Genentech, Janssen, Karus Therapeutics, LAM Therapeutics, and TG Therapeutics.
Publisher Copyright:
© 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
PY - 2021
Y1 - 2021
N2 - This study aimed to assess the prognostic value of baseline disease distribution for patients with the secondary central nervous system (CNS) diffuse large B-cell lymphoma (DLBCL) treated with chemotherapy and radiation (RT). 44 patients with secondary CNS DLBCL were reviewed. Twenty patients had leptomeningeal disease (LMD), and 24 had localized/targetable disease (LTD). Of 8 patients who received stem cell transplantation (SCT) after RT, 6 had LTD with a complete or partial response after RT. Median time to CNS relapse after RT was 10.1 months; 3/24 patients with LTD and 5/15 with LMD had CNS relapse. The median overall survival (OS) was 8 and 20 months for patients with LMD and LTD, respectively (p = 0.20). On multivariable analysis, LTD, receipt of SCT, and response after RT were associated with better OS and CNS-disease-free survival. Patients with localized secondary CNS DLBCL may benefit from RT serving as a bridge to SCT.
AB - This study aimed to assess the prognostic value of baseline disease distribution for patients with the secondary central nervous system (CNS) diffuse large B-cell lymphoma (DLBCL) treated with chemotherapy and radiation (RT). 44 patients with secondary CNS DLBCL were reviewed. Twenty patients had leptomeningeal disease (LMD), and 24 had localized/targetable disease (LTD). Of 8 patients who received stem cell transplantation (SCT) after RT, 6 had LTD with a complete or partial response after RT. Median time to CNS relapse after RT was 10.1 months; 3/24 patients with LTD and 5/15 with LMD had CNS relapse. The median overall survival (OS) was 8 and 20 months for patients with LMD and LTD, respectively (p = 0.20). On multivariable analysis, LTD, receipt of SCT, and response after RT were associated with better OS and CNS-disease-free survival. Patients with localized secondary CNS DLBCL may benefit from RT serving as a bridge to SCT.
KW - Diffuse large B-cell lymphoma
KW - central nervous system lymphoma
KW - radiation therapy
KW - salvage therapy
KW - stem cell transplantation
UR - http://www.scopus.com/inward/record.url?scp=85105130858&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85105130858&partnerID=8YFLogxK
U2 - 10.1080/10428194.2021.1919656
DO - 10.1080/10428194.2021.1919656
M3 - Article
C2 - 33942701
AN - SCOPUS:85105130858
SN - 1042-8194
VL - 62
SP - 2400
EP - 2407
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 10
ER -